SAIDAL Group, actor and instrument of national public health policy, aims to consolidate its leadership position in the pharmaceutical market and be a key player in open to new technologies and innovations highly competitive environment, with constant concern to preserve its brand and its sustainability.
In the Group's strategy, the quality is positioned as the central axis around which all actions are articulated management to ensure:
• The placing on the market of products comply with legal and regulatory requirements, particularly in terms of safety, security and efficiency.
• The well-being of patients.
The Group's objectives are implemented by constantly observing the component of its Corporate Social Responsibility core values:
• Citizen Solidarity